CASI | tickerfilter.com

Fundamental analysis

13%

Profitability 0%

Dept financing 12%

Liquidity 75%

Performance 11%

Company vs Stock growth

10.213 M 15.259 M

5.046 M 49.41%

N/A

+ Add row to compare

Performance

5 Days

-5.41%

1 Month

-10.27%

3 Months

-29.72%

6 Months

-64.74%

1 Year

-35.37%

2 Year

-36.49%

Key data

Stock price

$2.01

P/E Ratio

0.00

DAY RANGE

$2.01 - $2.05

EPS

-$0.41

52 WEEK RANGE

$1.90 - $7.67

52 WEEK CHANGE

-$35.78

MARKET CAP

101.888 M

YIELD

N/A

SHARES OUTSTANDING

15.461 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

1.44

PUBLIC FLOAT

AVERAGE 10 VOLUME

$15,010

AVERAGE 30 VOLUME

$11,181

Company detail

CEO: Wei-Wu He
Region: US
Website: casipharmaceuticals.com
Employees: 180
IPO year: 1996

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

CASI Pharmaceuticals, Inc. develops and commercializes therapeutics and pharmaceutical products. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL)

CASI - CASI Pharmaceuticals, Inc (DE)